PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER

QR Code

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER

Abstract: lung cancer takes the second place in the general structure of incidence of malignant neoplasms in Russia. The diagnosis of a local or metastatic non small cells lung cancer (NSCLC) serves the indication to carrying out the 1st line chemotherapy. In case of progressing against or after the...

Full description

Saved in:

Bibliographic Details
Main Author:	A. U. Kulikov
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2015-03-01
Series:	Фармакоэкономика
Subjects:	non small cells lung cancer erlotinib pemetrexed gefitinib docetaxel «cost-effectiveness» «cost-utility»
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/35
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review)
by: O.M. Smorodska, et al.
Published: (2021-06-01)

COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER
by: S. A. Protsenko, et al.
Published: (2017-01-01)

Experience of pemetrexed in maintenance therapy for metastatic lung adenocarcinoma
by: L. Yu. Vladimirova, et al.
Published: (2021-03-01)

RESULTS OF TREATMENT OF PATIENTS WITH LOCALLY ADVANCED AND METASTATIC NON-SQUAMOUS CELL NON-SMALL-CELL LUNG CARCINOMA WITH PEMETREXED (BY OWN EXPERIENCE)
by: L. Yu. Vladimirova, et al.
Published: (2016-04-01)

OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS
by: A. A. Kolomeytseva, et al.
Published: (2020-12-01)

GEFITINIB (IRESSA) IN THE TREATMENT OF BRAIN METASTASES FROM NON-SMALL CELL LUNG CARCINOMA
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

Botriomicosis asociada a tratamiento con erlotinib en una paciente con adenocarcinoma de pulmón
by: Claudia Montoya, et al.
Published: (2019-08-01)

Bullous fixed drug eruption due to erlotinib: A rare case report
by: Kallolinee Samal, et al.
Published: (2025-07-01)

EFFECT OF CHEMOTHERAPY WITH DOCETAXEL / CISPLATIN ON GRANULOCYTIC HEMOPOIESIS IN PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA
by: V. E. Goldberg, et al.
Published: (2016-11-01)

STUDI IN SILICO KOMPLEKS LIGAND-RESEPTOR EUGENOL DAUN BASIL (Ocimum basilicum L.) DENGAN RESEPTOR HER2 PADA NON-SMALL CELL LUNG CANCER (NSCLC) DENGAN KONTROL GEFITINIB
by: Martina Kurnia Rohmah
Published: (2017-09-01)

The efficacy and safety of intrathecal pemetrexed for leptomeningeal metastasis from non-small cell lung cancer: a single-arm meta-analysis of Chinese patients
by: Yushi Zhao, et al.
Published: (2025-06-01)

Successful use of docetaxel for emergency treatment of disseminated intravascular coagulation due to hormone-refractory metastatic prostate cancer
by: Serkan Keskin, et al.
Published: (2017-07-01)

Correction: The efficacy and safety of intrathecal pemetrexed for leptomeningeal metastasis from non-small cell lung cancer: a single-arm meta-analysis of Chinese patients
by: Yushi Zhao, et al.
Published: (2025-07-01)

Ginsenoside Rg3 Adjunctively Increases the Efficacy of Gefitinib Against NSCLC by Regulating EGFR Copy Number
by: Xinyi Lv, et al.
Published: (2025-07-01)

Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis
by: Yanjing Guo, et al.
Published: (2025-07-01)

Effect of Curcumin on Docetaxel-Induced Apoptosis in the DU145 (Prostate) Cell Line Using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide Assay
by: Mohammad Shokrzadeh, et al.
Published: (2025-07-01)

Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non–small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study
by: Natalia Fernández Núñez, et al.
Published: (2025-01-01)

Effect of the composition of combined solid lipid particles with gefitinib and a photosensitizer on their size, stability and cytotoxic activity
by: L. L. Nikolaeva, et al.
Published: (2024-07-01)

Unusual Cutaneous Reaction with Erlotinib: A Brief Report with Current Review of Management of Tyrosine Kinase Inhibitor-associated Cutaneous Toxicity
by: Aashita, et al.
Published: (2025-04-01)

Metformin-Sensitized Chemotherapy of Docetaxel Nanoemulsions Based on a Sequential Administration
by: Junlei Zhang, et al.
Published: (2025-06-01)

Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure
by: Zong-Han Yao, et al.
Published: (2025-08-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

Synergistic Effects of Carvacrol and Thymol on Docetaxel-Induced Cytotoxicity in the A549 Cell Line by Evaluating Cell Viability and Oxidative Stress
by: Mohammad Shokrzadeh, et al.
Published: (2025-07-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
by: Andrey Vladislavovich Pavlysh, et al.
Published: (2015-09-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-05-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-05-01)

MECHANISMS OF ACTIVATION OF HEMATOPOIETIC RECOVERY DUE TO FILGASTRIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY WITH DOXORUBICIN/DOCETAXEL
by: Т. Yu. Khrichkova, et al.
Published: (2016-02-01)

Results of combination treatment using docetaxel in an adjuvant chemotherapy regimen for resectable breast cancer
by: L. V. Bolotina, et al.
Published: (2014-07-01)

Preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal carcinosarcoma: a case report and review of the literature
by: Tomoko Yoshimoto, et al.
Published: (2018-02-01)

TAG Technical assessment guide
Published: (1982)

The Effect of Arsenic Trioxide and Its Combination with Oxaliplatin and Docetaxel on the Induction of Autophagy and Expression of LC3 and Beclin-1 Genes in AGS and MKN-45 Gastric Cancer Cell Lines
by: Shadi Babaei, et al.
Published: (2025-04-01)

Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price
by: D. A. Ivanov, et al.
Published: (2021-07-01)

Formation of Docetaxel-related Substances in the Polymer Particles During Storage and Gamma-treatment
by: Yu. I. Poltavets, et al.
Published: (2020-02-01)

Identification of Mitochondrial-Related Genes as Potential Biomarkers for Docetaxel-Resistant Prostate Cancer
by: Yalda Hekmatshoar
Published: (2025-06-01)

Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer
by: Yu. Yu. Petukhova, et al.
Published: (2021-10-01)

Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly
by: I. S. Krysanov, et al.
Published: (2025-05-01)

ANALYSIS OF ADVERSE DRUG REACTIONS (ADRs) AND THEIR SEVERITY IN BREAST CANCER PATIENTS TREATED WITH THE DOCETAXEL-DOXORUBICIN REGIMEN AT SULTAN AGUNG ISLAMIC HOSPITAL
by: Muh Maskur Setiaji, et al.
Published: (2025-07-01)

Economic analysis of power projects /
by: Desai, Nitin
Published: (1985)

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2016-06-01)

Reciprocal regulation between B lymphoma Mo-MLV insertion region 1 homolog and type I insulin-like growth factor receptor in pemetrexed-resistant lung cancer cells
by: Huan-Ting Shen, et al.
Published: (2025-07-01)